Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

v3.24.2.u1
License Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2015
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Feb. 28, 2023
Jan. 31, 2019
May 31, 2016
License Agreements                  
Issuance of common shares - Founders Agreement     $ 402,000 $ 396,000 $ 558,000        
Research and development                  
License Agreements                  
Issuance of common shares - Founders Agreement           $ 3,400,000      
NeuPharma, Inc. | Additional sales milestone                  
License Agreements                  
Maximum potential milestone payments $ 40,000,000.0                
NeuPharma, Inc. | Clinical and development milestone                  
License Agreements                  
Maximum potential milestone payments 39,000,000.0                
NeuPharma, Inc. | Regulatory approvals to commercialize the products                  
License Agreements                  
Maximum potential milestone payments 22,500,000                
Dana-Farber Cancer Institute                  
License Agreements                  
Amount of milestone expensed 5,000,000.0                
Maintenance fee 50,000                
Dana-Farber Cancer Institute | First commercial sale milestone                  
License Agreements                  
Maximum potential milestone payments 21,500,000                
Dana-Farber Cancer Institute | Additional sales milestone                  
License Agreements                  
Maximum potential milestone payments $ 60,000,000.0                
Adimab, LLC | PD-L1 | Research and development                  
License Agreements                  
Non-Refundable milestone payment             $ 2,200,000    
Adimab, LLC | Clinical and development milestone                  
License Agreements                  
Maximum potential milestone payments               $ 2,500,000  
Jubilant Biosys Limited | Additional sales milestone                  
License Agreements                  
Maximum potential milestone payments                 $ 89,300,000
Jubilant Biosys Limited | Regulatory approvals to commercialize the products                  
License Agreements                  
Maximum potential milestone payments                 59,500,000
Jubilant Biosys Limited | Clinical development and regulatory milestones                  
License Agreements                  
Maximum potential milestone payments                 $ 88,400,000
Collaboration Agreement With TGTX                  
License Agreements                  
Revenue recognition milestone revenue recognized   $ 41,000 12,000 $ 41,000 41,000        
Sublicense Agreement with TGTX                  
License Agreements                  
Revenue recognition milestone revenue recognized     $ 18,000   $ 24,000